OX2R News & Analysis

Lilly (LLY) to Acquire Centessa for OX2R Sleep Disorders

Lilly (LLY) announced the acquisition of Centessa Pharmaceuticals, focusing on OX2R drug candidates for sleep disorders. This strategic move aims to enhance LLY's portfolio in the sleep medicine market, which has seen increasing demand. Financial terms of the deal were not disclosed, but the acquisition is anticipated to bolster LLY's research and development capabilities. The market impact could reflect positively on LLY's stock as they expand their therapeutic offerings.